Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04569435 · ClinicalTrials.gov registry record · Phase 2
Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study, sponsored by Annexon.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT04569435: Completed Phase 2 study, sponsored by Annexon.
NCT04569435 is a Phase 2 study that has completed, run by Annexon. The registered enrollment target is 17 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04569435, a Phase 2 study, has completed, sponsored by Annexon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with ALS.
Interventions
- DRUG ANX005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2024-04-23 |
| Phase | Phase 2 |
What the finished NCT04569435 record still lists
NCT04569435 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which ANX005 is the first listed.
NCT04569435 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04569435 about?
NCT04569435 is a clinical study titled "Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)". This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with ALS.
What is the current status of trial NCT04569435?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2021-01-15. Estimated completion is 2024-04-23.
What interventions are being tested in trial NCT04569435?
The interventions under investigation include: ANX005 (DRUG).
Who is sponsoring clinical trial NCT04569435?
This trial is sponsored by Annexon, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04569435's enrollment target sits among peer trials
17 1903rd of 2000 higher than 93 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI